ArticleFrontiers in oncology2026
Case Report: Borderline type I/II cryoglobulinemia associated with marginal zone lymphoma: a diagnostic challenge.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryoglobulinemia comprises heterogeneous disorders caused by immunoglobulins that precipitate at low temperatures, leading to vascular occlusion and immune-mediated tissue injury. Type I disease is typically linked to monoclonal gammopathies, whereas mixed forms (Type II or III) are characterized by immune complex-mediated vasculitis, rheumatoid factor activity, and renal involvement. The immune complexes are generally composed of IgM rheumatoid factor and IgG. We describe a 67-year-old woman with marginal zone lymphoma who developed an unusual cryoglobulinemia phenotype combining monoclonal IgM-κ cryoglobulins with clinical features characteristic of mixed disease, including purpura, transient rheumatoid factor positivity, and renal impairment. Diagnosis was delayed due to initial false-negative cryoglobulin testing and atypical presentation. Despite rituximab therapy, subsequent R-CVP, and intensive plasmapheresis, the patient's condition progressed, ultimately requiring bendamustine-rituximab, after which she deteriorated and died shortly after discharge. The exceptional nature of this case lies the concomitant clinical manifestation of Type I and Type II cryoglobulinemia, which complicated the diagnostic process and therapeutic management. This case underscores a significant diagnostic challenge in hematology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.